Press release
Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association
LEXINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that four abstracts will be presented from the KER-050 and ALK2 hematology programs at the 26th Annual Congress of the European Hematology Association (“EHA”), to be held as a virtual event from June 9-17, 2021. “We are pleased to present additional mechanistic preclinical data for KER-050, which further demonstrate that KER-050 potentially promotes differentiation of both early- and terminal-stage progenitor cells, at this year’s virtual Congress. These data further support our belief that KER-050 can potentially treat diseases that exhibit defects in different stages of erythropoiesis, such as myelodysplastic syndromes and myelofibrosis. Additionally, new preclinical data from our ALK2 program provide further evidence of the effects of ALK2 inhibition on hepcidin and iron metabolism to potentially resolve anemias,” said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros. “Separately, we remain on track to provide a program update on KER-050 with initial data from Part 1 of our Phase 2 clinical trial of KER-050 in patients with myelodysplastic syndromes to be announced by the end of June 2021.” Details of the presentations are as follows: “KER-050, an inhibitor of TGF-β superfamily signaling, observed to have a rapid, dynamic, and durable effect on erythropoiesis” Abstract Number: EP758Date and Time: Virtual poster presentation available June 11-17, 2021 “ALK2 is a potential therapeutic target in anemia resulting from chronic inflammation” Abstract Number: EP839Date and Time: Virtual poster presentation available June 11-17, 2021 “ALK2 inhibition, a novel therapeutic approach to iron overload” Abstract Number: EP842Date and Time: Virtual poster presentation available June 11-17, 2021 “Administration of ALK2 neutralizing antibodies to cynomolgus monkeys led to a sustained decrease in hepcidin, increase in circulating iron and increase in erythrocyte hemoglobin” Abstract Number: EP840Date and Time: Virtual poster presentation available June 11-17, 2021 About KER-050 Keros’ lead protein ...